Last reviewed · How we verify
Brimonidine/Timolol mixed combination
Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways.
Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Brimonidine/Timolol mixed combination |
|---|---|
| Also known as | Combigan |
| Sponsor | Seoul National University Hospital |
| Drug class | Alpha-2 adrenergic agonist / Beta-blocker combination |
| Target | Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine stimulates alpha-2 adrenergic receptors to decrease aqueous humor production and increase uveoscleral outflow. Timolol blocks beta-adrenergic receptors to reduce aqueous humor production. The combination provides additive IOP-lowering effects through complementary mechanisms.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Dry eye
- Allergic conjunctivitis
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: